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  Background  Individual studies have suggested that some circulating fatty acids are associated with prostate cancer risk, but 
have not been large enough to provide precise estimates of associations, particularly by stage and grade of disease.
  Methods  Principal investigators of prospective studies on circulating fatty acids and prostate cancer were invited to col-
laborate. Investigators provided individual participant data on circulating fatty acids (weight percent) and other 
characteristics of prostate cancer cases and controls. Prostate cancer risk by study-specific fifths of 14 fatty acids 
was estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.
  Results  Five thousand and ninety-eight case patients and 6649 control patients from seven studies with an average 
follow-up of 5.1 (SD = 3.3) years were included. Stearic acid (18:0) was inversely associated with total prostate 
cancer (odds ratio [OR] Q5 vs Q1 = 0.88, 95% confidence interval [CI]  = 0.78 to 1.00, Ptrend = .043). Prostate cancer 
risk was, respectively, 14% and 16% greater in the highest fifth of eicosapentaenoic acid (20:5n-3) (OR = 1.14, 95% 
CI = 1.01 to 1.29, Ptrend = .001) and docosapentaenoic acid (22:5n-3) (OR = 1.16, 95% CI = 1.02 to 1.33, Ptrend = .003), 
but in each case there was heterogeneity between studies (P = .022 and P < .001, respectively). There was hetero-
geneity in the association between docosapentaenoic acid and prostate cancer by grade of disease (P = .006); the 
association was statistically significant for low-grade disease but not high-grade disease. The remaining 11 fatty 
acids were not statistically associated with total prostate cancer risk.
 Conclusion  There was no strong evidence that circulating fatty acids are important predictors of prostate cancer risk. It is not 
clear whether the modest associations of stearic, eicosapentaenoic, and docosapentaenoic acid are causal.
    JNCI J Natl Cancer Inst (2014) 106(9): dju240 doi:10.1093/jnci/dju240
International comparison studies have suggested that factors related 
to a western lifestyle, such as diet, may be important determinants 
of the worldwide variation in prostate cancer rates (1,2). A higher 
intake of foods such as red meat and dairy products, which are rich in 
saturated fatty acids, and a lower intake of marine-derived n-3 long-
chain polyunsaturated fatty acids (eicosapentaenoic [20:5n-3] and 
docosahexaenoic acid [22:6n-3]) are dietary factors that have been 
proposed to increase the risk of prostate cancer (3). Because it is dif-
ficult to obtain accurate and precise information on the consumption 
of individual fatty acids using conventional assessment methods such 
as dietary questionnaires, circulating concentrations of fatty acids (in 
serum, plasma, erythrocyte membranes, or whole blood) may be a bet-
ter measure for assessing the associations of individual fatty acids with 
prostate cancer risk (4,5). Furthermore, fatty acids in the blood also 
reflect the endogenous synthesis of certain fatty acids (5), a process 
that cannot be captured by assessing the dietary intake of fatty acids.
To date, the association between circulating fatty acids and risk 
of prostate cancer has been examined in 10 individual prospective 
studies (6–15), but these have not been large enough to provide 
precise estimates of associations, especially by stage and grade of 
disease. Moreover, it is difficult to evaluate the evidence for an 
association of some individual fatty acids with prostate cancer risk 
from the published data alone, because some studies have not pre-
sented data for the full range of fatty acids measured.
The Endogenous Hormones, Nutritional Biomarkers and 
Prostate Cancer Collaborative Group was established with the aim 
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of reanalyzing individual data from prospective studies of the asso-
ciations of circulating concentrations of hormones and nutritional 
biomarkers with risk of prostate cancer (16). The objective of this 
study was to examine the associations between the proportional 
concentrations of 14 circulating fatty acids and subsequent risk of 
prostate cancer in a collaborative reanalysis of individual participant 
data from seven prospective studies and to determine whether any 
associations differ by stage and grade of the disease or other factors.
Methods
Data Sources and Searches
Studies were eligible to join this collaborative group if they had 
data on circulating fatty acids measured in blood samples collected 
before the diagnosis of prostate cancer and had identified at least 
75 incident cases during follow-up. Studies were identified through 
searches using the search terms “fatty acids” and “prostate cancer” 
on computerized bibliographic systems, including PubMed, Web 
of Science, Cochrane Library, and CancerLit, through the refer-
ence lists of publications identified in this search and through dis-
cussions with colleagues. In 2004, the principal investigators who 
had published studies on prostate cancer risk and endogenous sex 
hormones and growth factors measured in blood samples collected 
before the diagnosis of prostate cancer and which included at least 
50 cases were invited to join the collaboration. In 2010, collabo-
rators were invited to update their data on endogenous sex hor-
mones and growth factors and to include any data on nutritional 
biomarkers and prostate cancer. Seven out of the nine published 
prospective studies that met the inclusion criteria provided fatty 
acid data for this collaboration (9–15). Two published studies of 
141 case patients and 282 control patients (6) and 198 case patients 
and 198 control patients (7) invited to participate were unable to 
join this collaboration.
Study Selection and Data Extraction
Individual participant data on circulating fatty acids were available 
from seven prospective studies: the Carotene and Retinol Efficacy 
Trial (CARET) (15), the European Prospective Investigation 
into Cancer and Nutrition (EPIC) study (10), the Melbourne 
Collaborative Cohort Study (MCCS) (13), the Multiethnic Cohort 
(MEC) (11), the Prostate Cancer Prevention Trial (PCPT) (12), the 
Physicians’ Health Study (PHS) (9), and the Selenium and Vitamin 
E Cancer Prevention Trial (SELECT) (14). These included 5098 
case patients and 6649 control patients, representing almost 95% of 
the worldwide prospective data on fatty acids and prostate cancer. 
Where available, collaborators provided data for case patients and 
control patients on date, age, time of blood collection, fasting sta-
tus, marital status, ethnicity, educational attainment, family history 
of prostate cancer, height, weight, smoking status, alcohol intake, 
and prostate-specific antigen (PSA) concentration. Information on 
stage and grade for prostate cancer case patients was also provided 
where available. The data obtained from the collaborators was 
summarized and then sent back to collaborators for final checking 
and confirmation. In order to provide a common definition across 
studies, a cancer was defined as being advanced if it was tumor-
node-metastasis (TNM) stage T3 or T4 and/or N1+ and/or M1, 
stage III–IV, or the equivalent (that is, a tumor extending beyond 
the prostate capsule and/or lymph node involvement and/or distant 
metastases), localized if it was TNM stage T0 or T1 or T2 with no 
reported lymph node involvement or metastases, stage 0–II, or the 
equivalent (that is, a tumor which does not extend beyond the pros-
tate capsule), or stage unknown. Aggressive disease was categorized 
as “yes” for TNM stage T4 and/or N1+ and/or M1 and/or stage IV 
disease or death from prostate cancer, “no” for TNM stage T0, T1, 
T2, or T3 with no reported lymph node involvement or metastases 
or the equivalent, or unknown. Prostate cancer was defined as high 
grade if the Gleason sum was at least 8 or the equivalent (undif-
ferentiated), low grade if the Gleason sum was less than 8 or the 
equivalent (extent of differentiation good, moderate, or poor), or 
grade unknown. Grade was based on Gleason sums for CARET, 
PCPT, and SELECT (17), on extent of differentiation for MEC, 
and on a mixture of both systems for EPIC, MCCS, and PHS. It 
should be noted that in the previous publications from these stud-
ies a Gleason sum of 7 or above was classed as high grade, with the 
exception of PCPT, where a Gleason sum of 8 or above was used.
Supplementary Table 1 (available online) shows the character-
istics of the seven studies included in this collaboration. Details of 
the recruitment of participants, informed consent, ethical approval, 
and inclusion criteria are available in the original publications (9–
15). Two of the seven studies used a matched case-control study 
design nested within a prospective study (10,11). Three studies 
used a matched case-control study design nested within a rand-
omized controlled trial (9,12,15). For this collaboration, the PCPT 
study contributed men in the placebo arm of the trial, because the 
intervention group (who were given the drug finasteride) had a 
lower risk of prostate cancer than the controls, but CARET and 
PHS included all men regardless of whether they were in the 
control or the intervention group. In these five studies (CARET, 
EPIC, MEC, PCPT, and PHS), blood samples were collected from 
men who were healthy at recruitment and then followed to identify 
those who developed prostate cancer. The fatty acid analyses were 
performed on blood samples from the participants diagnosed with 
incident prostate cancer and from the control participants who 
were matched to these cases on certain characteristics such as age 
at blood collection and date of blood collection (Supplementary 
Table 1, available online). One study (13) used a case-cohort design 
nested within a prospective study where fatty acids were measured 
for all incident cases of prostate cancer and a random sample of 
the cohort. For this analysis, matched case-control sets were cre-
ated from the case-cohort study by randomly matching up to two 
control participants to each case by age at blood collection, date 
of recruitment, assay batch number, and country of birth. The 
SELECT study used a case-cohort design nested within a rand-
omized controlled trial (14). For this analysis, one control was 
matched to each case by age at blood collection and ethnicity.
Details of the assay methods for the measurement of circulating 
fatty acids are shown in Supplementary Table 2 (available online); five 
of the studies measured the fatty acid composition of plasma or serum 
phospholipids, MEC measured fatty acids in erythrocyte membranes, 
and PHS measured the fatty acid composition of whole blood. Of 
the five studies that measured the fatty acid composition of serum 
or plasma phospholipids, four studies (CARET, MCCS, PCPT, and 
SELECT) used thin-layer chromatography to separate out the phos-
pholipids, whereas the EPIC study used solid phase extraction.JNCI | Review 3 of 10 jnci.oxfordjournals.org
Data Synthesis and Analysis
For each of the 14 fatty acids, men were categorized into fifths of 
its circulating proportion (calculated as a relative weight percent 
of the total fatty acids), with cut points defined by the study-spe-
cific quintiles of the distribution within control participants. This 
was to allow for any systematic differences between the studies in 
assay methods and blood sample types (18). We also examined the 
associations of study-specific fifths of the following groups of fatty 
acids with prostate cancer risk: total n-6 polyunsaturated fatty acids 
(sum of linoleic, dihomo-gamma-linolenic, and arachidonic acid), 
total n-3 polyunsaturated fatty acids (sum of alpha-linolenic, eicos-
apentaenoic, docosapentaenoic, and docosahexaenoic acid), the 
ratio of total n-6 to n-3 polyunsaturated fatty acids, long-chain n-6 
polyunsaturated fatty acids (sum of dihomo-gamma-linolenic and 
arachidonic acid), long-chain n-3 polyunsaturated fatty acids (sum 
of eicosapentaenoic, docosapentaenoic, and docosahexaenoic acid), 
and the ratio of long-chain n-6 to n-3 polyunsaturated fatty acids.
The main method of analysis was logistic regression condi-
tioned on the matching variables within each study. To provide a 
summary measure of the odds ratio (for subgroup analyses) and to 
calculate a Ptrend, the categorical variable representing the fifths of 
the circulating fatty acid was replaced with a continuous variable 
that was scored as 0, 0.25, 0.5, 0.75, and 1; because the mid-points 
of the lowest and highest fifths are the 10th and 90th percentiles of 
the study-specific proportion of fatty acids, a unit increase in this 
variable can be taken to represent an 80 percentile increase in the 
study-specific proportion of the fatty acid. Body mass index (BMI; 
<25, 25–27.4, 27.5–29.9, ≥30  kg/m2, or not known), height (<170, 
171–175, 176–180, >180 cm, or not known), marital status (married 
or cohabiting, not married and cohabiting, or not known), educa-
tional status (did not graduate from high school/secondary school/
college, high school/secondary school/college graduates, university 
graduates, or not known), cigarette smoking (never smoker, past 
smoker, current smokers, or not known), and age at blood collec-
tion (continuous) were all statistically significantly related to pros-
tate cancer risk in these analyses (P < .05) and were included in 
the conditional logistic regression models. For each fatty acid, het-
erogeneity in linear trends between studies was tested by compar-
ing the χ2 values for models with and without an (study) x (linear 
trend) interaction term. To test whether the linear-trend odds ratio 
estimates for each fatty acid varied according to certain case-par-
ticipant characteristics, odds ratios were estimated within a series 
of subsets for the following characteristics: age at diagnosis (<60, 
60–69, or ≥70 years), years from blood collection to diagnosis (<3, 
3–6, or ≥7 years), year of diagnosis (pre-1990, 1990–1994, 1995–
1999, or 2000 onwards), stage of disease (localized or advanced), 
aggressive disease (no or yes), and grade of disease (low or high). 
Control patients in each matched set were assigned the value of 
their matched case for the case-defined factors (eg, age at diagnosis 
and years from blood collection to diagnosis). For PCPT where 
the matched sets contained multiple case patients, the proportion 
of case patients in each category (excluding the “unknowns”) of the 
case-defined variable within the matched set was calculated, and 
the controls in the matched set were randomly allocated to these 
categories in the same proportion. For aggressive disease, we also 
conducted further analyses restricted to these case patients and 
their matched control patients, calculating odds ratios in fifths of 
the distribution in control patients. Subgroup analyses were also 
conducted according to the following participant characteristics: 
age at blood draw (<60 or ≥60 years), PSA at blood draw (<2 or 
≥2 ng/mL, based on the median value), university or higher educa-
tion (no or yes), BMI (<25 or ≥25 kg/m2), cigarette smoking (never/
past smoker or current smoker), usual alcohol consumption (<10 or 
≥10 g/day), and family history of prostate cancer (no or yes). Tests for 
heterogeneity for the case-defined factors were obtained by fitting 
separate models for each subgroup and assuming independence of 
the odds ratios using a method analogous to a meta-analysis. Tests 
for heterogeneity for the non-case-defined factors were assessed 
using a χ2-test of interaction between subgroup and the continuous 
trend test variable. Results in the figures are presented as squares 
and lines, representing the odds ratios and corresponding 95% 
confidence intervals (CIs), respectively. The position of the square 
indicates the value of the odds ratio, while the size of the square is 
inversely proportional to the variance of the logarithm of the odds 
ratio and indicates the amount of statistical information available 
for that particular estimate. The open diamonds (the lateral points 
of which are the 95% CIs) represent the overall odds ratio for an 
80 percentile increase in the individual fatty acids.
All statistical analyses were carried out using Stata (StataCorp, 
2011, Stata Statistical Software: Release 13, College Station, TX). All 
P values reported are two-sided and a P value less than .05 was 
considered statistically significant.
Results
Five thousand and ninety-eight case patients and 6649 control 
patients from seven studies with an average follow-up of 5.1 (SD 
3.3) years were included. The characteristics of participants in each 
study according to their case-control status are shown in Table 1. 
The mean age at recruitment across studies ranged from 58 to 
69 years, and the average BMI of men ranged from 24 to 29 kg/m2. 
The majority of men were married (or cohabiting), and the propor-
tion of men who were current smokers ranged from less than 10% 
in PCPT, PHS, and SELECT to over 50% in the CARET study. 
The mean alcohol intake ranged from less than 10 g/day in PCPT, 
PHS, and SELECT to over 20 g/day in EPIC and MEC.
Most of the case patients were older than 60 years at diagno-
sis and were diagnosed with prostate cancer from 1995 onwards 
(Table 2). The proportion of case patients whose blood was col-
lected at least seven years before diagnosis ranged from approxi-
mately 1% in SELECT to 74% in PHS. Of the case patients with 
information on stage of disease, the majority were localized, rang-
ing from 71% in EPIC to 99% in SELECT. Similarly, the propor-
tion of case patients with low-grade (that is, a Gleason score <8 or 
equivalent) ranged from 86% in EPIC to 100% in MEC.
The medians and interquartile ranges of the 14 fatty acids that 
make up approximately 90% to 95% of total fatty acids for case 
patients and control patients in each of the studies are shown in 
Table 3. The median proportions of the five fatty acids making 
up about 80% of the total fatty acids in the five studies (CARET, 
EPIC, MCCS, PCPT, and SELECT) that measured phospholipid 
fatty acids in serum or plasma were around 25% to 27% for pal-
mitic acid (16:0), 11% to 14% for stearic acid (18:0), 8% to 10% 
for oleic acid (18:1n-9), 19% to 26% for linoleic acid (18:2n-6), Vol. 106, Issue 9  |  dju240  |  September 10, 2014 4 of 10  Review | JNCI
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and 9% to 11% for arachidonic acid (20:4n-6). For the fatty acid 
composition of erythrocyte membranes measured in MEC, these 
median values were 30%, 22%, 16%, 12%, and 9%, respectively, 
and, for the fatty acid composition of whole blood in the PHS, they 
were 20%, 10%, 17%, 25%, and 10%, respectively. There were no 
large differences in the median proportions of fatty acids between 
case patients and control patients.
For the saturated and monounsaturated fatty acids (Figure 1), 
there were no associations of the proportions of myristic (14:0), 
pentadecanoic (15:0), palmitic acid (16:0), heptadecanoic acid 
(17:0), palmitoleic acid (16:1n-7), or oleic acid with risk of total 
prostate cancer. However, stearic acid (18:0) was inversely related 
to total prostate cancer risk; compared with men in the lowest fifth, 
men in the highest fifth had a 12% lower risk (OR = 0.88, 95% 
CI = 0.78 to 1.00, Ptrend = .043).
For the polyunsaturated fatty acids (Figure 2), there was no sta-
tistical association between alpha-linolenic acid (18:3n-3) composi-
tion and total prostate cancer risk; the odds ratio for the highest fifth 
compared with the lowest fifth was 1.03 (95% CI = 0.91 to 1.17). 
Eicosapentaenoic acid was positively related to risk of total prostate 
cancer (OR for the highest compared with the lowest fifth = 1.14, 
95% CI = 1.01 to 1.29, Ptrend = .001), as was n-3 docosapentae-
noic acid (22:5n-3) (OR for the highest compared with the lowest 
fifth = 1.16, 95% CI = 1.02 to 1.33, Ptrend = .003), but docosahexae-
noic acid was not statistically associated with risk. There were no 
statistical associations between the proportions of the three major 
n-6 polyunsaturated fatty acids, linoleic, dihomo-gamma-linolenic 
(20:3n-6), and arachidonic, and total prostate cancer risk.
Results for groups of fatty acids, study-specific and subgroup 
analyses are shown in Supplementary Figures 1–30 (available 
online). There was a statistically significant inverse association 
between total n-6 polyunsaturated fatty acids and prostate cancer 
(Ptrend = .022) but no statistical association with the long-chain n-6 
fatty acids (Ptrend = .472) (Supplementary Figure 1, available online). 
The odds ratios for the highest vs the lowest fifth of total and long-
chain n-3 polyunsaturated fatty acids were 1.16 (95% CI = 1.02 to 
1.31, Ptrend =0.013) and 1.17 (95% CI = 1.03 to 1.32, Ptrend = .011), 
respectively. There were statistically significant inverse associations 
of both n-6 to n-3 ratios with prostate cancer risk; the odds ratios 
for the highest vs the lowest fifth of the total and long-chain n-6 to 
n-3 ratios were 0.85 (95% CI = 0.74 to 0.96, Ptrend = .005) and 0.78 
(95% CI = 0.69 to 0.89, Ptrend = .003), respectively.
There was evidence for heterogeneity between stud-
ies for eicosapentaenoic acid and docosapentaenoic acid with 
risk of total prostate cancer (P = .022 and <.001, respectively) 
(Supplementary Figures 10 and 11, available online). There was 
also evidence for heterogeneity between studies in the asso-
ciations of palmitoleic acid and prostate cancer risk (P = .039) 
(Supplementary Figure 7, available online), and dihomo-gamma-
linolenic acid and prostate cancer (P = .015) (Supplementary 
Figure 14, available online).
The associations of stearic acid did not differ by age at diag-
nosis, years from blood collection to diagnosis, year of diagnosis, 
stage of disease, presence of aggressive disease, grade of disease, 
age at blood draw, PSA concentration at blood draw, university 
education, BMI, smoking status, alcohol consumption, or fam-
ily history of prostate cancer (Pheterogeneity > .05) (Supplementary 
Figure  20, available online). Eicosapentaenoic acid was statisti-
cally significantly positively associated with prostate cancer risk in 
men without a university education but not in more educated men 
(Pheterogeneity = .003), among men aged 60 years and over at blood 
draw but not in younger men (Pheterogeneity = .024), and among men 
without a family history of prostate cancer but not in men with 
a history of prostate cancer (Pheterogeneity  =  .044) (Supplementary 
Figure 24, available online). Docosapentaenoic acid was statisti-
cally significantly positively associated with prostate cancer risk in 
men diagnosed from year 2000 onwards but not among men diag-
nosed prior to this (Pheterogeneity < .001), among men with low grade 
disease (OR for an 80 percentile increase = 1.24, 95% CI = 1.10 
to 1.41) but not in men with high grade disease (OR = 0.68, 95% 
CI = 0.45 to 1.03, Pheterogeneity = .006), and among men aged 60 years 
and over at blood draw but not in younger men (Pheterogeneity = .047) 
(Supplementary Figure 25, available online). The subgroup results 
for the other fatty acids are in Supplementary Figures 16–19, 21–
23, and 26–29 (available online). Of the 143 tests for heterogeneity 
presented in these figures, there was statistically significant het-
erogeneity for myristic acid and age at diagnosis (Supplementary 
Figure  16, available online), palmitoleic acid and grade of dis-
ease (Supplementary Figure 21, available online), alpha-linolenic 
acid and both stage of prostate cancer and alcohol consumption 
(Supplementary Figure 23, available online), and arachidonic acid 
and both aggressive disease and cigarette smoking (Supplementary 
Figure 29, available online).In further analyses of the 14 fatty acids 
in relation to the risk for aggressive prostate cancer (Supplementary 
Figure 30, A and B, available online), the only association found 
was that the risk of aggressive disease was lower in men with the 
highest proportion of arachidonic acid (OR highest vs the lowest 
fifth = 0.70, 95% CI = 0.45 to 1.10, Ptrend = .040).
Discussion
The main findings from this collaboration were that men with 
lower concentrations of stearic acid and higher concentrations 
of eicosapentaenoic and docosapentaenoic acid had a modestly 
(approximately 15%) greater risk of developing prostate cancer, 
which did not differ by stage or aggressiveness of disease. This col-
laboration has brought together and reanalyzed data from seven 
prospective studies, representing almost 95% of the worldwide 
data on the association between circulating fatty acids and prostate 
cancer risk. While data from the Janus study of 141 case patients 
(6) and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention 
Study (ATBC) of 198 case patients (7) were not available for this 
analysis, their results do not differ materially from those reported 
here, and it is unlikely that these data would change the associa-
tions described.
A higher proportion of stearic acid was associated with a lower 
risk of total prostate cancer. While short-term studies have shown 
that an increased consumption of foods rich in stearic acid increases 
the proportion of these fatty acids in the circulation (19–21), such 
relations have not been seen in some studies of long-term intake in 
free-living populations (22), suggesting that the level of this fatty 
acid in blood does not provide a simple index of intake (23). Besides 
dietary intake, lower levels of stearic acid in the blood could be 
a result of altered metabolism of this fatty acid (24), although JNCI | Review 7 of 10 jnci.oxfordjournals.org
evidence for these pathways being implicated in the development 
of prostate cancer is limited. While we did not observe statistically 
significant heterogeneity in the association of stearic acid with risk 
of prostate cancer according to the number of years between blood 
collection and diagnosis, some reverse causation bias is still pos-
sible, because the latency period of prostate cancer might be up to 
10 years (25).
Both eicosapentaenoic and docosapentaenoic acid were weakly 
positively associated with prostate cancer risk; however, there was 
heterogeneity between studies. There were statistically significant 
positive associations in EPIC and SELECT for eicosapentaenoic 
acid, and in PCPT and SELECT for docosapentaenoic acid but 
statistically significant inverse associations for eicosapentaenoic and 
docosapentaenoic acid in the PHS. There were differences between 
the studies in the types of blood samples used to measure fatty acids; 
the PHS was the only study to measure the fatty acid composition 
of whole blood; however, we accounted for this difference by divid-
ing participants into study-specific fifths (18). It is possible that dif-
ferences between studies in the underlying participant population 
(eg, men participating in a randomized trial vs an observational 
study) might account for some of this heterogeneity. It is there-
fore difficult to draw any conclusions about eicosapentaenoic and 
Figure 1.  Odds ratios and 95% CIs for prostate cancer by study-specific fifths of circulating saturated and monounsaturated fatty acids. The odds 
ratios were conditioned on the matching variables and adjusted for age, marital status, education level, cigarette smoking, height, and BMI. The 
Ptrend was calculated by replacing the fifths of the fatty acid with a continuous variable that was scored as 0, 0.25, 0.5, 0.75, and 1 in the conditional 
logistic regression model. All statistical tests were two-sided. 80%le = 80 percentile; CI = confidence interval; Ptr = Ptrend.Vol. 106, Issue 9  |  dju240  |  September 10, 2014 8 of 10  Review | JNCI
docosapentaenoic acid from this analysis. A possible explanation for 
the positive associations between eicosapentaenoic and docosapen-
taenoic acid and total prostate cancer risk might involve the behavior 
of health-conscious men who may have both a high consumption of 
fish and a relatively high likelihood of having a PSA test in countries 
where the overall rate of PSA testing is lower than in the United 
States (26–28). This has been previously described in the PHS (29). 
Although the positive associations of circulating eicosapentaenoic 
acid and docosapentaenoic acid with prostate cancer risk did not dif-
fer statistically significantly according to whether the prostate cancer 
was diagnosed before or after the introduction of PSA testing in the 
early 1990s, the risk was greater in post-2000 cancers than in ear-
lier cancers, and the study that showed statistically inverse associa-
tions of eicosapentaenoic and docosapentaenoic acid with prostate 
cancer risk (PHS) had a large proportion of cases diagnosed before 
1995, suggesting that these discrepant associations might be partly 
explained by detection bias. Further support for this idea comes from 
the findings of statistically positive associations of docosapentaenoic 
acid with localized, nonaggressive and low-grade disease but not 
advanced, aggressive, or high-grade prostate cancer.
The results from this study do not support the hypothesis 
that a higher proportion of alpha-linolenic acid increases the risk 
Figure 2.  Odds ratios and 95% CIs for prostate cancer by study-specific fifths of circulating polyunsaturated fatty acids. The odds ratios were condi-
tioned on the matching variables and adjusted for age, marital status, education level, cigarette smoking, height, and BMI. The Ptrend was calculated 
by replacing the fifths of the fatty acid with a continuous variable that was scored as 0, 0.25, 0.5, 0.75, and 1 in the conditional logistic regression 
model. All statistical tests were two-sided. 80%le = 80 percentile; CI = confidence interval; Ptr = Ptrend.JNCI | Review 9 of 10 jnci.oxfordjournals.org
of prostate cancer, as reported in an earlier analysis of the PHS 
(30). A recent meta-analysis of published results from 16 studies 
reported an overall positive association between alpha-linolenic 
acid and prostate cancer risk (31), but this was based on both retro-
spective and prospective studies and studies of both dietary intake 
and tissue levels. Our results, showing little or no association, rep-
resent the most up-to-date and comprehensive summary of the 
prospective association between circulating alpha-linolenic acid 
and prostate cancer risk.
For the other fatty acids examined, there was no evidence for 
associations with risk for total prostate cancer. The supplemen-
tary analyses of the sums of n-6 and n-3 fatty acids and their ratios 
showed some statistically significant associations, but these results 
are largely predictable from the results for the individual fatty 
acids and are difficult to interpret. Several analyses described in 
the Supplementary figures (available online) showed heterogene-
ity between studies or subgroups, but these results are difficult to 
interpret because of the large number of comparisons made, mak-
ing it difficult to rule out the play of chance. However, the finding 
of a statistically inverse association between arachidonic acid and 
aggressive prostate cancer is of potential interest. While there have 
been many experimental studies examining the putative effects of 
arachidonic acid on promoting prostate cancer initiation and pro-
gression (32), there is almost no evidence to support mechanisms 
whereby arachidonic acid inhibits prostate cancer progression.
These results represent the associations of prostate cancer 
risk with fatty acid measures from a single blood sample for each 
man, taken on average five years before cancer diagnosis in the 
cases. The extent to which a single blood sample reflects long-
term values has not been studied extensively, but a study of serum 
phospholipid fatty acids in blood samples taken three to four years 
apart reported correlation coefficients of 0.7 for stearic acid and 
0.5 for eicosapentaenoic acid (33). This might mean that the asso-
ciations between the “usual” proportion of circulating fatty acids 
and total prostate cancer risk are likely to be stronger than those 
reported here.
In summary, the results from this collaborative analysis of over 
5000 cases and 6000 controls showed that men with lower circulat-
ing stearic acid and higher eicosapentaenoic and docosapentaenoic 
acid had a slightly elevated risk of developing total prostate cancer. 
However, it is not clear whether these modest associations indicate 
any causal relationships between fatty acids and prostate cancer 
risk.
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